Regeneron Pharmaceuticals

Reports highlight recent developments from Regeneron Pharmaceuticals

Published in Medical Verdicts and Law Weekly, January 18th, 2007

Reports highlight recent developments from Regeneron Pharmaceuticals.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Regeneron Pharmaceuticals.

Report 1: Bayer HealthCare (BAY) and Regeneron Pharmaceuticals, Inc., (REGN) announced that the companies have entered into a collaboration agreement for the global development, and commercialization outside the U.S., of the VEGF Trap for the treatment of eye disease by local administration (VEGF Trap-Eye).

The VEGF Trap-Eye, currently in phase I and phase II clinical trials, is a protein that binds to or "traps" vascular endothelial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly

Source: Medical Verdicts and Law Weekly (2007-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry